bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) – Equities researchers at SVB Leerink issued their Q1 2023 earnings per share estimates for shares of bluebird bio in a research report issued on Monday, January 23rd. SVB Leerink analyst M. Foroohar anticipates that the biotechnology company will post earnings per share of ($0.64) for the quarter. SVB Leerink currently has a "Market Perform" rating and a $8.00 price objective on the stock. The consensus estimate for bluebird bio's current full-year earnings is ($4.36) per share. SVB Leerink also issued estimates for bluebird bio's Q2 2023 earnings at ($0.62) EPS and Q3 2023 earnings at ($0.58) EPS.Get bluebird bio alerts:
BLUE has been the subject of several other research reports. Morgan Stanley raised their target price on bluebird bio from $3.00 to $4.00 and gave the stock an "underweight" rating in a research report on Tuesday. Royal Bank of Canada cut their target price on bluebird bio to $8.00 and set a "sector perform" rating for the company in a research report on Tuesday, November 8th. Finally, StockNews.com initiated coverage on bluebird bio in a research report on Wednesday, October 12th. They set a "sell" rating for the company. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $6.75.
bluebird bio Trading Up 5.5 %Shares of BLUE stock opened at $6.53 on Tuesday. The stock has a 50 day moving average of $7.40 and a two-hundred day moving average of $6.52. bluebird bio has a 12 month low of $2.87 and a 12 month high of $8.58. The company has a market capitalization of $541.49 million, a P/E ratio of -1.07 and a beta of 0.99.
bluebird bio (NASDAQ:BLUE – Get Rating) last announced its quarterly earnings data on Monday, November 7th. The biotechnology company reported ($0.92) EPS for the quarter, topping analysts' consensus estimates of ($1.28) by $0.36. bluebird bio had a negative return on equity of 173.58% and a negative net margin of 8,828.28%. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $2.25 million.
Insider Activity at bluebird bio
In related news, Director Nick Leschly sold 4,290 shares of the firm's stock in a transaction on Wednesday, January 11th. The stock was sold at an average price of $7.80, for a total transaction of $33,462.00. Following the completion of the sale, the director now directly owns 280,149 shares of the company's stock, valued at approximately $2,185,162.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 9,506 shares of company stock valued at $72,088 in the last three months. Corporate insiders own 2.20% of the company's stock.
Institutional Investors Weigh In On bluebird bio
Hedge funds and other institutional investors have recently made changes to their positions in the company. Metropolitan Life Insurance Co NY increased its stake in shares of bluebird bio by 142.4% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 4,671 shares of the biotechnology company's stock valued at $30,000 after buying an additional 2,744 shares during the period. US Bancorp DE increased its stake in shares of bluebird bio by 234.9% in the 3rd quarter. US Bancorp DE now owns 7,918 shares of the biotechnology company's stock valued at $50,000 after buying an additional 5,554 shares during the period. Amalgamated Bank bought a new position in shares of bluebird bio in the 1st quarter worth $39,000. PEAK6 Investments LLC bought a new position in shares of bluebird bio in the 2nd quarter worth $41,000. Finally, Laurion Capital Management LP bought a new position in shares of bluebird bio in the 2nd quarter worth $42,000. 79.01% of the stock is owned by institutional investors and hedge funds.
About bluebird bio
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Can Coty Stock Emerge in 2023 With Upside
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
- Insiders Buy Archer Aviation, Is This Stock About To Take Off?
- Intuit Is About To Make a Move, But Which Way?
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.